Dramatic response of a gastrointestinal stromal tumor to neadjuvant imatinib therapy

Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the alimentary tract and are believed to derive from the interstitial Cell of Cajal. Imatinib mesylate (Gleevec(®); Novartis, Basel, Switzerland) has revolutionized the treatment of GISTs and is generally used in the metastatic a...

Descripción completa

Detalles Bibliográficos
Autores principales: Annaberdyev, Shohrat, Gibbons, Joseph, Hardacre, Jeffrey M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661077/
https://www.ncbi.nlm.nih.gov/pubmed/19291285
http://dx.doi.org/10.1186/1477-7819-7-30
Descripción
Sumario:Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the alimentary tract and are believed to derive from the interstitial Cell of Cajal. Imatinib mesylate (Gleevec(®); Novartis, Basel, Switzerland) has revolutionized the treatment of GISTs and is generally used in the metastatic and adjuvant settings. We report the case of a 61-year old man who was treated with neoadjuvant imatinib for a massive gastric GIST with the hope of avoiding a potential multi-visceral resection.

Ejemplares similares